Company intelligence / Profile preview
Lenire Biosciences
Los Angeles, California, United Stateslenirebiosciences.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Lenire Biosciences is developing VSN16R, a small molecule positive modulator of BK channels, licensed from UCL. VSN16R has completed phase II trials for other indications but is in pre-clinical/early clinical evaluation for Fragile X Syndrome. Preclinical models show efficacy in rescuing FXS-related phenotypes; no clinical results for FXS are available yet.[2][3][4]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University College London (UCL) (technology license)Collaboration with Cincinnati Children’s Hospital Medical Center (Dr. Craig Erickson, Fragile X Research and Treatment Center)
Beyond the preview
Go deeper on Lenire Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lenire Biosciences.